The Mohammed VI Foundation for Science and Health and GlaxoSmithKline Morocco SA signed a strategic partnership agreement on Tuesday in Rabat, aimed at enhancing their cooperation in the fields of biomedical research, therapeutic innovation, and continuous improvement of medical practices in Morocco.
This partnership is part of a shared vision focused on scientific and medical progress in service to citizens’ health. It relies on the complementary expertise of both institutions, with the Mohammed VI Foundation being a reference player in training, research, and care, while GlaxoSmithKline is one of the global leaders in the pharmaceutical industry, recognized for its commitment to the research and development of specialized medicines and vaccines.
Through this agreement, the two parties intend to implement joint structural actions designed to support the evolution of medical practices and strengthen the skills of healthcare professionals. The partnership notably includes the development and deployment of continuing education programs, as well as continuous medical training initiatives aimed at updating scientific knowledge and improving clinical skills.
Cooperation will also focus on organizing awareness campaigns regarding diseases within hospital facilities, notably through the establishment of pilot projects, as well as the generation, analysis, and valorization of scientific data. These efforts will be conducted in strict compliance with existing ethical, scientific, and regulatory standards, to contribute to a better understanding of health issues and improve care pathways.
By signing this agreement, the Mohammed VI Foundation for Science and Health and GlaxoSmithKline Morocco SA reaffirm their joint commitment to research, innovation, and medical excellence, with the goal of supporting the development of the national health system towards increasingly effective and patient-centered practices.
